References
- Medical Research Council (MRC). Aids to the Investigation of Peripheral Nerve Injuries. London: Her Majesty’s Stationery Office, 1976.
- Lacomblez L, Bensimon G, Leigh PN et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyo- trophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–1431.
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–591.
- Great Lakes ALS Study Group. Inter- and intra-observer reproducibility between medical centers assessing strength with manual muscle testing and computerized maximal vol- untary isometric contractions and their sensitivity for pro- gression over time in ALS. 11th International Symposium on ALS/MND. ALS 2000; 1(Suppl 3): 4–5.
- ALS CNTF Treatment Study Group. A double-blind placebo- controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyo- trophic lateral sclerosis. Neurology 1996; 46: 1244–1249.
- Miller RG, Petajan JH et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 1996; 39: 256–260.
- Miller RG, Moore D, Young LA et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1383–1388.
- Miller RG, Moore DH, Gelinas DF et al. Phase III random- ized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–848.
- Miller RG, Sheppard R, Dao H et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc Disord 1996; 6: 101–104.
- ALS CNTF Treatment Study Group: A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyo- trophic lateral sclerosis. Neurology 1996; 46: 1244–1249.
- Goonetilleke A, Modarres-Sadeghi H, Guiloff RJ. Accuracy, reproducibility, and variability of hand-held dynamometry in motor neuron disease. J Neurol Neurosurg Psychiatry 1994; 57: 326–332.
- Beck M, Giess R, Wurffel W et al. Comparison of maximal voluntary isometric contraction and Drachman’s hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve 1999; 22: 1265–1270.
- Hoagland RJ, Mendoza M, Armon C et al. Reliability of maximal voluntary isometric contraction testing in a multi- center study of patients with amyotrophic lateral sclerosis. Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group. Muscle Nerve 1997; 20: 691–695.
- Brooks BR, Sanjak M, Belden DS, Waclawik AJ. Motor neurone disease: Basic designs, sample sizes and pitfalls. In: RJ Guiloff, ed. Clinical Trials in Neurology. London: Springer Verlag, 2001; 427–448.
- Andres PL, Skerry LM, Thornell B, Portney LG. Finison LJ. Munsat TL. A comparison of three measures of disease pro- gression in ALS. J Neurol Sci 1996; 139(Suppl): 64–70.
- The National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehab 1996; 77: 1251–1255.
- Ringel SP, Murphy JR, Alderson MK et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316–1322.
- Stambler N, Charatan M, Cedarbaum JM and the ALS CNTF Study Group. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology 1998; 50: 66–72.